The FDA on Tuesday approved the first-ever hepatitis C treatment that can tackle all six major forms of the HCV virus—and it’ll be available for a lower price than many had anticipated.
The drug, biotech giant Gilead’s (gild) Epclusa, won regulators’ blessing to treat all chronic hep C patients both with and without advanced liver disease. The therapy combines Gilead’s blockbuster (and controversially priced) hepatitis medication Sovaldi with a new compound called velpatasvir.
Gilead’s dominance in the hepatitis C drug market has been fueled by groundbreaking products like Sovaldi and Harvoni which have essentially cured the liver-ravaging disease. After 12 weeks of treatment, Epclusa was shown to rid any detectable traces of HCV in 95-99% of tested patients across three late-stage clinical trials.
Click here to subscribe to our new Brainstorm Health Daily Newsletter.
But the company has also faced an onslaught of criticism over its drugs’ high list prices (although these top-line costs don’t include discounts and rebates to insurers, benefit managers, and patients). Sovaldi gained notoriety as the “$1,000 pill” and drew the ire of a bipartisan U.S. Senate report essentially alleging the company put profits over patients when determining its price tag. Gilead has responded that its treatments are far more cost-effective in the long run compared with liver transplants for uncured patients whose disease progresses.
This time, the company’s taking a different tact—one that could actually wind up lowering costs for the approximately 25% of American hep C patients with rarer and more difficult-to-treat strains of the virus like HCV genotypes 2 and 3.
Epclusa will be priced at $74,760 for a 12-week treatment regimen, or $890 per pill. That may not seem like a huge discount over $1,000 per pill. But as the biotech told the San Francisco Business Times, it’s half as expensive as currently available options for HCV genotype 3 patients.
Still, the price tweak failed to impress those who argue that Gilead’s aggressive intellectual property tactics are inflating costs for patients and the broader health sector. One organization that’s been a persistent Gilead critic, the affordable medicines advocacy group the Initiatives for Medicines, Access & Knowledge (I-MAK), slammed the company’s Epclusa pricing and habit of pursuing secondary patents to extend and “evergreen” a product’s original patent life.
“The price point Gilead is charging is enabled by over 35 patents that have been granted to date when they should not have been,” said I-MAK co-director Tahir Amin in a statement. “Gilead is abusing the patent system and driving prices out of reach, making it hard for consumers to have affordable access to treatment, and forcing taxpayers to foot the bill.”